Two Novel DHDDS Mutations Add to Epilepsy-Movement Disorder Spectrum

Researchers in China have identified two previously unreported DHDDS variants in patients presenting with epilepsy and movement disorders, publishing their findings alongside an updated literature review in Seizure: European Journal of Epilepsy, available online 13 October 2026.

The study comes from a 14-author team led by Guoping Ren and Qun Wang, with co-authors including Ruijuan Lv, Shengsong Wang, Xiaoqiu Shao and Maomao Liu. The group spans neurology, epileptology and genetics — a mix that signals where DHDDS work now sits: at the junction of the reading room and the sequencing lab.

DHDDS encodes dehydrodolichyl diphosphate synthase, a enzyme in the mevalonate pathway. Variants in this gene have been linked to a phenotype that combines seizures with abnormal movements, and the new report adds two fresh mutations to that catalog while consolidating what the published record has accumulated so far.

What does this change for the EEG reader?

For clinical neurophysiologists, the practical relevance is phenotypic recognition. A patient whose scalp EEG shows epileptiform discharges and who also displays movement disorder features — dystonia, chorea, tremor or paroxysmal events on video-EEG monitoring — may warrant DHDDS sequencing rather than a standard epilepsy gene panel that omits it.

The movement-disorder component matters diagnostically. On a monitoring unit, paroxysmal motor events can look epileptic on history alone. Careful correlation of the ictal scalp EEG with the semiology on video, and where needed EMG to characterize the movement phenotype, is what separates the two. That distinction drives the genetic workup.

How was the review constructed?

The authors systematically updated prior literature on DHDDS-related disease, folding their own two novel cases into an appraisal of the wider cohort of reported patients. The journal has not yet released full cohort numbers in the abstract stage; readers should treat the detailed genotype-phenotype correlations as pending the final print version.

What the publication date establishes is momentum. The gene was not historically part of routine epilepsy panels. Each additional case report — and this one adds two mutations at once — strengthens the argument for including DHDDS when the clinical picture combines epilepsy with movement disorders.

Investigational or established?

The genetic findings themselves are diagnostic-grade laboratory work, not device claims, so the FDA-cleared-versus-investigational distinction does not apply here. No BCI or neurofeedback element is involved. The evidence base is human clinical data: reported patients, not animal models, which is the strongest tier available for a rare-disease gene review.

Why the mevalonate pathway matters

DHDDS operates in cholesterol and dolichol biosynthesis — the same pathway implicated in other metabolic epilepsies and, notably, in the mechanism of statin-associated neurological effects. For readers who follow metabolic epileptology, the gene's pathway position helps explain why the phenotype crosses systems: brain excitability and motor control both depend on dolichol-dependent glycosylation.

The review format means clinicians get a synthesis, not just isolated case descriptions. Aggregating reported mutations lets the authors map which variants associate with which seizure types and movement phenotypes, and where the EEG signature — if a consistent one exists — fits in.

Who should act on this?

Three groups, concretely:

• Epileptologists ordering genetic testing for developmental and epileptic encephalopathies with movement features;
• Clinical neurophysiologists on monitoring units distinguishing epileptic from non-epileptic paroxysmal events;
• Genetic counselors explaining recurrence risk in families with confirmed DHDDS variants.

The paper's publication in Seizure, the European Journal of Epilepsy, places it squarely in the specialty's mainstream rather than a biochemistry niche.

What comes next

Watch for the full text to specify the two novel variants at the nucleotide and protein level, the ages at onset, and the seizure types documented on EEG. Larger multicenter cohorts will be needed to firm up genotype-phenotype correlations, and this updated review, online since 13 October 2026, gives investigators a consolidated baseline from which to build them.